Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.17
-2.3%
$0.18
$0.12
$3.39
$1.42M-0.03992,531 shs31,705 shs
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$0.88
$0.88
$0.62
$1.47
$26.53M1.221,000 shsN/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
$3.16
-3.2%
$2.99
$0.15
$1.27
$145.84M-0.4314.23 million shs4,783 shs
Teligent, Inc. stock logo
TLGT
Teligent
$0.03
$0.17
$1.60
N/AN/AN/A6,460 shs
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$2.03
-0.7%
$2.28
$1.90
$4.21
$58.31M0.61178,043 shs107,238 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%-2.90%-8.66%-4.58%-90.40%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00%0.00%0.00%0.00%0.00%
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
0.00%-10.99%-20.67%-4.53%+1,808.21%
Teligent, Inc. stock logo
TLGT
Teligent
0.00%0.00%0.00%0.00%0.00%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
0.00%+2.79%-14.56%-13.83%-38.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
2.5608 of 5 stars
3.55.00.00.00.00.01.3
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/AN/AN/AN/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
1.5707 of 5 stars
0.05.00.00.01.11.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
3.00
Buy$20.0011,609.60% Upside
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
0.00
N/AN/AN/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
0.00
N/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
0.00
N/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest VTGN, TLGT, RTTR, PXSLY, and BPTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
$8.75M3.03N/AN/A$0.04 per share22.00
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
N/AN/AN/AN/A$0.10 per shareN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
$490K120.51N/AN/A$2.44 per share0.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%8/13/2025 (Estimated)
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
-$9.36MN/A0.00N/AN/AN/AN/AN/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
-$10.13MN/AN/AN/AN/AN/A-162.05%N/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/A0.00N/AN/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$51.42M-$1.66N/AN/AN/A-6,777.08%-58.88%-52.38%8/12/2025 (Estimated)

Latest VTGN, TLGT, RTTR, PXSLY, and BPTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/AN/AN/AN/AN/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
N/AN/AN/AN/AN/A
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
2.82
3.31
2.92
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
N/A
3.67
3.67
Teligent, Inc. stock logo
TLGT
Teligent
N/AN/AN/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
N/A
6.51
6.51

Institutional Ownership

CompanyInstitutional Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
0.84%
Teligent, Inc. stock logo
TLGT
Teligent
N/A
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
78.39%

Insider Ownership

CompanyInsider Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
N/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
15.40%
Teligent, Inc. stock logo
TLGT
Teligent
0.17%
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
1.29%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
108.31 million5.73 millionOptionable
Pharmaxis Ltd stock logo
PXSLY
Pharmaxis
6930.15 millionN/ANot Optionable
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
746.15 millionN/ANot Optionable
Teligent, Inc. stock logo
TLGT
Teligent
2,357N/AN/AOptionable
VistaGen Therapeutics, Inc. stock logo
VTGN
VistaGen Therapeutics
4029.16 million28.78 millionOptionable

Recent News About These Companies

VTGN Vistagen Therapeutics, Inc. - Seeking Alpha
Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.17 0.00 (-2.29%)
As of 07/3/2025 12:20 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Pharmaxis stock logo

Pharmaxis OTCMKTS:PXSLY

$0.88 0.00 (0.00%)
As of 06/8/2021

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

Ritter Pharmaceuticals stock logo

Ritter Pharmaceuticals NASDAQ:RTTR

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Teligent stock logo

Teligent NASDAQ:TLGT

Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.

VistaGen Therapeutics stock logo

VistaGen Therapeutics NASDAQ:VTGN

$2.02 -0.02 (-0.74%)
Closing price 07/3/2025 03:33 PM Eastern
Extended Trading
$2.03 +0.00 (+0.25%)
As of 07/3/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.